Syndax Q1 2021 Earnings Report
Key Takeaways
Syndax Pharmaceuticals reported a net loss attributable to common stockholders of $27.7 million, or $0.54 per share, for the first quarter ended March 31, 2021. As of March 31, 2021, Syndax had cash, cash equivalents and short-term investments of $271.3 million.
Two prior responders from AUGMENT-101 trial of SNDX-5613 achieved full count recovery, bringing CR/CRh rate upto 23%.
Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21.
Enrollment of 23 cGVHD patients in Phase 2 expansion cohort testing axatilimab at 1 mg/kg complete; enrollment ongoing in pivotal AGAVE-201 trial of axatilimab in cGVHD.
New data from Phase 1 dose escalation portion of the Phase 1/2 AUGMENT-101 trial of SNDX-5613 showed two prior responders have improved from CRp to CR with no evidence of minimal residual disease (MRD-).
Syndax
Syndax
Forward Guidance
For the second quarter of 2021, research and development expenses are expected to be $30 to $35 million, and total operating expenses are expected to be $35 to $40 million. For the full year of 2021, research and development expenses are expected to be $90 to $100 million, and total operating expenses are expected to be $110 to $120 million.